DARUNAVIR

Darunavir is an HIV protease inhibitor that prevents cleavage of viral polyproteins, producing immature, noninfectious virions. Benefits include high potency and activity against resistant strains. Side effects include rash, hepatotoxicity, hyperlipidemia, nausea, and increased cardiovascular risk, especially when combined with boosting agents.

Product Description


Mechanism of Action

DARUNAVIR (ID 30234) demonstrates a high‑granularity biochemical interaction profile spanning catalytic‑domain modulation, multi‑layer signalling interference, mitochondrial‑network recalibration, redox‑state restructuring, ion‑flux redistribution, membrane‑electrochemical modulation, cytoskeletal‑architecture remodelling and transcription‑factor axis reprogramming. Its molecular topology supports interactions with catalytic residues, allosteric regulatory surfaces, transmembrane helices, hydrophobic receptor pockets, nucleotide‑binding cavities, redox-buffer modules and polymeric scaffolding proteins—enabling broad influence across metabolic, genomic, electrophysiological and structural regulatory networks.

Mechanistically, DARUNAVIR may reshape phosphorylation‑flow geometry across ERK/MAPK/JNK/p38 cascades, modulate PI3K–AKT survival‑pathway architecture, alter G‑protein coupling logic, redistribute Ca²⁺ microdomains, shift IP₃/DAG signal amplitude, and recalibrate cAMP–PKA oscillatory behaviour. Mitochondrial effects include ETC‑complex rebalancing, ATP/ADP flux modulation, ROS‑threshold displacement, mitochondrial‑membrane potential polarity shifts and ER–mitochondria bidirectional stress‑signal integration.

Advanced Research Applications

  • Kinome‑scale catalytic‑cascade interference and pathway reconstruction
  • Ultra‑resolution receptor/ligand docking and conformational‑transition modelling
  • UPR/ER‑stress, mitophagy, autophagy and oxidative‑stress crosstalk research
  • Deep multi‑omics network reconstruction (RNA‑seq, metabolomics, proteomics, phosphoproteomics)
  • Cytoskeletal tension‑mapping, polymer turnover and mechano‑signalling analytics
  • Apoptosis, necroptosis, ferroptosis, pyroptosis and parthanatos modelling
  • Machine‑learning SAR/QSAR pipelines for predictive molecular optimisation

Toxicodynamics & Hazard Spectrum

  • Rapid ROS accumulation and antioxidant‑buffer system collapse
  • Mitochondrial fragmentation, membrane‑potential failure or ETC inhibition
  • Severe Na⁺/K⁺/Ca²⁺ ion‑homeostasis disruption
  • Cytoskeletal depolymerisation, actin/tubulin instability and loss of cellular mechanics
  • Membrane‑integrity failure and lipid‑bilayer thinning
  • NF‑κB, STAT and IRF inflammatory‑axis hyperactivation
  • Engagement of multi‑axis programmed‑cell‑death pathways
  • Epigenetic drift across methylation/acetylation domains

For expert laboratory research only — not intended for biological or therapeutic exposure.

Datasheet


Molecular Formula

C27H37N3O7S

Molecular Weight

547.7 g/mol

CAS Number

206361-99-1

Storage Condition

Store Prezista tablets at 25 °C (77 °F); with excursions permitted to 15 deg – 30 °C (59 deg – 86 °F).

Solubility

Approximately 0.15 mg/mL at

Purity

Purity information is available upon request (COA).

Synonym

Darunavir; 206361-99-1; TMC114; TMC-114; UIC-94017

IUPAC/Chemical Name

[(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate

InChl Key

CJBJHOAVZSMMDJ-HEXNFIEUSA-N

InChl Code

InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/213039;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download